ACT for Infertility in India: Regenerative Reproductive Medicine at ALIV | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

ALIV's ACT programme for reproductive health is delivered under the clinical leadership of Dr. Sunita Tandulwadkar — a gynaecological endocrinologist with decades of specialist fertility experience and the distinction of being associated with India's landmark cases in reproductive medicine. The reproductive health ACT programme at ALIV reflects the convergence of Dr. Tandulwadkar's clinical expertise and ALIV's regenerative medicine approach: applying autologous paracrine regenerative support to specific reproductive challenges where conventional fertility management has reached its limits.

Applications in Reproductive Medicine

Diminished Ovarian Reserve (DOR) and Premature Ovarian Insufficiency (POI): These conditions — characterised by low AMH, elevated FSH, and reduced ovarian follicle pools — represent the most clinically challenging scenarios in female fertility. Conventional fertility management has limited tools for increasing ovarian reserve. ALIV's ovarian ACT programme uses autologous platelet-rich preparations and MSC-derived growth factors — including VEGF (supporting ovarian angiogenesis), IGF-1 (supporting folliculogenesis), and anti-inflammatory signals (reducing the follicular inflammatory environment that impairs oocyte development) — administered to or near the ovarian tissue. The clinical goal is supporting the development and function of remaining follicles rather than creating new ones — a meaningful distinction. Results are variable and this is an experimental application.

Thin Endometrium: An endometrial thickness below 7mm significantly impairs implantation — even in the setting of high-quality embryos. Conventional management with oestrogen, sildenafil, and aspirin has limited efficacy in refractory thin endometrium. ACT preparations rich in VEGF and endometrial repair growth factors, administered via intrauterine or intravenous routes, aim to support endometrial vascularity and thickness through paracrine stimulation of endometrial regeneration. This is one of the most scientifically plausible regenerative applications in reproductive medicine and has been explored in early clinical studies. ALIV's approach in this area reflects Dr. Tandulwadkar's specific clinical expertise.

Uterine Synechiae (Asherman's Syndrome) Post-Surgical Repair: Following surgical division of intrauterine adhesions, ACT can be used as an adjunctive intervention to support endometrial regeneration and reduce the risk of readhesion — supporting the healing endometrium in the post-surgical period to achieve better functional endometrial restoration.

What Patients Should Understand

ACT in reproductive medicine is explicitly experimental — the evidence base is at an earlier stage of development than for musculoskeletal or even neurological applications. Positive outcomes (improved AMH, improved cycle response, successful IVF cycles in previously failed patients) are reported in ALIV's clinical experience and in the early-phase literature, but are not predictable or guaranteed. The patient selection and outcome expectation conversation for reproductive ACT is the most delicate and carefully conducted in ALIV's clinical practice — the emotional stakes of fertility treatment require complete honesty about what is and is not achievable before any intervention is undertaken. See the general ACT framework: ACT results timeline.

Is ALIV's reproductive ACT the same as "ovarian rejuvenation"?

Ovarian rejuvenation is the most common marketing term for autologous growth factor application to the ovary for fertility purposes — often using PRP or ACT preparations. ALIV's approach is grounded in the same biological principle but differs in clinical rigour: comprehensive pre-procedure assessment, careful patient selection, defined clinical protocols under Dr. Tandulwadkar's direct supervision, and honest outcome communication. The term "ovarian rejuvenation" is not used at ALIV because it implies a predictability and certainty that is not supported by current evidence. What ALIV offers is autologous paracrine support for ovarian and endometrial function in carefully selected patients.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.